H-色氨酰-蛋氨酸 | 21438-63-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: H-色氨酰-蛋氨酸
• 英文名称: Trp-Met
• 英文别名: L-Methionine, L-tryptophyl-；(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-4-methylsulfanylbutanoic acid
• CAS: 21438-63-1
• 化学式: C₁₆H₂₁N₃O₃S
• 分子量: 335.427
• InChiKey: BVZABQIRMYTKCF-JSGCOSHPSA-N

物化性质

• 沸点：
  689.6±55.0 °C(Predicted)
• 密度：
  1.327±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  138
• 氢给体数：
  3
• 氢受体数：
  4

制备方法与用途

H-Trp-Met-OH是一种具有生物活性的肽。

反应信息

• 作为产物：
  描述：

  四肽胃泌素 在 modified endoproteinase Asp-N from Pseudomonas fragi 作用下， 以 水 为溶剂， 反应 3.0h， 生成 H-色氨酰-蛋氨酸
  参考文献：
  名称：

  Solid-state stability studies of cholecystokinin (CCK-4) peptide under nonisothermal conditions using thermal analysis, chromatography and mass spectrometry

  摘要：

  The solid-state stability of cholecystokinin (CCK-4) peptide under nonisothermal conditions was studied by differential scanning calorimetry (DSC), chromatography and mass spectrometry, identifying and schematizing the degradation products. To model the degradation mechanism of the peptide using the combined Kissinger and direct-differential methods, the observed degradation process was characterized by decomposition temperature (T-m), reacted fraction (alpha(m)), activation energy (E-a), and pre-exponential factor (A). Results obtained by the two calculation methods were similar.The cleavage reaction on both N- and C-terminal sides of aspartic acid was the principal degradation pathway, although the reaction can occur consecutively and/or in parallel. Therefore to determine the relative importance of the different degradation pathways, a system of differential equations relevant to each degradation reaction was analysed using the R(R) statistical program. The results obtained show that the consecutive reaction was the less plausible, whereas a slightly better fit was obtained for the reaction with both processes than for the in-parallel reaction. In this situation, the F-test was applied to discriminate between the models, indicating that the simpler model is the most probable. In conclusion, the results demonstrate for the first time that, in solid-state, n-1 cleavage occurs in parallel to n+1 cleavage at aspartic acid residues and not consecutively. (C) 2010 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ejps.2009.12.010

文献信息

• MUTANT PROTEIN HAVING THE PEPTIDE-SYNTHESIZING ACTIVITY
  申请人：ABE Isao

  公开号：US20070292916A1

  公开（公告）日：2007-12-20

  The present invention aims at providing an excellent peptide-synthesizing protein and a method for efficiently producing a peptide. The peptide is synthesized by reacting an amine component and a carboxy component in the presence of at least one of proteins shown in the following (I) and (II). (I) The mutant protein having an amino acid sequence comprising one or more mutations from any of the mutations 1 to 68, and the mutations 239 to 290 and 324 to 377 in an amino acid sequence of SEQ ID NO:2. (II) The mutant protein having an amino acid sequence comprising one or more mutations from any of the mutations L1 to L335 and M1 to M642 in an amino acid sequence of SEQ ID NO:208

  本发明旨在提供一种优秀的肽合成蛋白质及高效生产肽的方法。在以下（I）和（II）所示的蛋白质的至少一种存在下，通过在胺组分和羧组分存在下反应合成肽。其中，（I）为突变蛋白质，其氨基酸序列包括来自于突变1至突变68、突变239至突变290和突变324至突变377的一个或多个突变；（II）为突变蛋白质，其氨基酸序列包括来自于L1至L335和M1至M642的一个或多个突变。
• Mutant protein having the peptide-synthesizing activity
  申请人：Abe Isao

  公开号：US20070190602A1

  公开（公告）日：2007-08-16

  The present invention aims at providing an excellent peptide-synthesizing protein and a method for efficiently producing a peptide. The peptide is synthesized by reacting an amine component and a carboxy component in the presence of at least one of proteins shown in the following (I) and (II). (I) The mutant protein having an amino acid sequence comprising one or more mutations from any of the mutations 1 to 68, and the mutations 239 to 290 and 324 to 377 in an amino acid sequence of SEQ ID NO:2. (II) The mutant protein having an amino acid sequence comprising one or more mutations from any of the mutations L1 to L335 and M1 to M642 in an amino acid sequence of SEQ ID NO:208

  本发明旨在提供一种优异的合成肽蛋白质及高效生产肽的方法。在以下(I)和(II)所示的蛋白质的存在下，通过反应胺组分和羧基组分来合成肽。(I)突变蛋白质的氨基酸序列包括来自突变1到68和突变239到290以及SEQ ID NO:2的氨基酸序列中的突变324到377中的一个或多个突变。(II)突变蛋白质的氨基酸序列包括来自突变L1到L335和M1到M642和SEQ ID NO:208的氨基酸序列中的一个或多个突变。
• MUTANT PROTEIN HAVING PEPTIDE-PRODUCTION ACTIVITY
  申请人：Ajinomoto Co., Inc.

  公开号：EP1829968A1

  公开（公告）日：2007-09-05

  The present invention aims at providing an excellent peptide-synthesizing protein and a method for efficiently producing a peptide. The peptide is synthesized by reacting an amine component and a carboxy component in the presence of at least one of proteins shown in the following (I) and (II). (I) The mutant protein having an amino acid sequence comprising one or more mutations from any of the mutations 1 to 68, and the mutations 239 to 290 and 324 to 377 in an amino acid sequence of SEQ ID NO:2. (II) The mutant protein having an amino acid sequence comprising one or more mutations from any of the mutations L1 to L335 and M1 to M642 in an amino acid sequence of SEQ ID NO:208

  本发明旨在提供一种优良的多肽合成蛋白和一种高效生产多肽的方法。该多肽是在至少一种如下(I)和(II)所示的蛋白质存在下，通过胺组分和羧基组分反应合成的。 (I)突变体蛋白质，其氨基酸序列包含 SEQ ID NO:2 的氨基酸序列中的突变 1 至 68、突变 239 至 290 和突变 324 至 377 中的一个或多个突变。 (II)突变体蛋白质，其氨基酸序列包含以下突变中的一个或多个突变 SEQ ID NO:208 的氨基酸序列中的 L1 至 L335 突变和 M1 至 M642 突变中的任一个或多个突变的突变体蛋白。
• ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM
  申请人：Ajinomoto Co., Inc.

  公开号：EP3604503A1

  公开（公告）日：2020-02-05

  The present invention provides a medium for culturing pluripotency stem cells, containing L-tryptophan or L-tryptophan derivative at a concentration of not less than 176 µM.

  本发明提供了一种培养多能干细胞的培养基，其中含有浓度不低于 176 µM 的 L-色氨酸或 L-色氨酸衍生物。
• METHOD FOR PRODUCING PEPTIDES
  申请人：ABE ISAO

  公开号：US20110262962A1

  公开（公告）日：2011-10-27

  The present invention provides a method for producing a peptide, comprising culturing a transformant introduced with an expression vector to prepare a culture, and mixing the culture with a carboxy component and an amine component to form the peptide. The expression vector comprises a polynucleotide encoding a protein: (A) having selected deletions in the amino acid sequence of SEQ ID NO:2, (B) having a mutation of one or several amino acid residues in any protein selected from said group (A); (C) having 70% or more amino acid sequence identity to any protein selected from said group (A), (D) encoded by a polynucleotide that hybridizes under a stringent condition with a polynucleotide consisting of a nucleotide sequence complementary to a polynucleotide encoding any protein selected from said group (A), and (E) encoded by a polynucleotide having 70% or more nucleotide sequence identity to the polynucleotide encoding any protein selected from the group (A).